Explore Thymalin dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Thymalin is a multi-peptide thymic extract developed at the St. Petersburg Institute of Bioregulation under Morozov and Khavinson in the 1970s-1980s — the original Khavinson cytomedine-class compound and the conceptual predecessor of the synthetic short-peptide bioregulator family that followed. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when reconstituting Thymalin.
Thymalin is the multi-peptide thymic extract developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vyacheslav Morozov and Vladimir Khatskelevich Khavinson in the late 1970s and 1980s — the original cytomedine-class compound and the conceptual ancestor of the entire Khavinson short-peptide bioregulator family that followed. Where the synthetic 2-4 amino acid bioregulators (Vilon, Livagen, Testagen, Prostamax) are chemically defined single peptides matching specific sequences derived from organ extracts, Thymalin is the upstream complex multi-peptide extract from young calf thymic tissue, prepared by acid hydrolysis and ultrafiltration to retain the low-molecular-weight peptide fraction.
Thymalin is a thymic polypeptide preparation (a fraction of thymus-derived peptides, not a single sequence) studied for immune-modulation research. It ships as a lyophilized powder, and because it's a mixture rather than one molecule, the certificate of analysis (COA) and source documentation matter more than a single purity number.
Thymalin is proposed to act as a multi-component immunomodulatory preparation, with effects on T-cell maturation, CD4/CD8 balance, and cytokine production attributed to the mixture rather than to any single defined molecule. Because Thymalin is a polypeptide mixture, its precise pharmacology is not characterised at the level of a single active species.
Russian observational cohorts and a long-running Khavinson-group observational follow-up have reported Thymalin (often in combination with Epithalon) in elderly immune-decline cohorts, with reported reductions in infection-frequency, improvements in T-cell subset distributions, and a programme-level mortality signal published as part of the broader Khavinson long-term cohort work. These studies are non-blinded, single-region, and have not been independently replicated outside Russia; no Western Phase 2 or 3 trial has been registered.
Thymalin has a reported half-life of ~1 hour (estimate), and the dose intervals researchers model most often fall around once daily (in 5–10 day courses). This thymic peptide complex clears from plasma within hours and is run in short courses; the immune effect is thought to outlast the course rather than depend on a steady blood level. It is catalogued under Anti-Aging Peptides on WPA.
5 Thymalin reconstitution calculations have been logged by the WPA community. The most common dose entered is 10mg (4 calculations). The most common bacteriostatic water volume is 5mL. The most popular vial size is 10mg (2 sessions). The most common dosing frequency is daily (7x/week) (1 logged protocols).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.